Here are the 424B prospectus supplements from Semnur Pharms Inc WTS (SMNRW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SMNRW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMNRW filings page.
Semnur Pharmaceuticals filed a prospectus supplement and attached Form 10-Q updating its S-1 registration. The supplement registers up to 203,737,349 shares for resale by selling securityholders and up to 7,432,122 shares issuable upon exercise of warrants, and registers 510,000 private warrants for resale.
The Form 10-Q shows $0.1M cash at March 31, 2026, a three-month net loss of $4.6M, accumulated deficit of $280.4M, and 230,209,142 shares outstanding as of April 25, 2026. Management discloses substantial doubt about going concern and dependence on Scilex for funding.
Semnur Pharmaceuticals, Inc. is registering the resale of up to 203,737,349 shares of Common Stock, the registration of up to 7,432,122 shares issuable upon exercise of warrants and up to 510,000 warrants for resale and exercise as described herein, to be offered from time to time by selling securityholders.
The company will receive proceeds only from cash exercises of the Warrants and not from resales by the selling securityholders. The prospectus discloses that Semnur completed a business combination and domestication on September 22, 2025, trades on the OTC Pink as SMNR and SMNRW, and reported last sale prices on May 15, 2026 of $5.99 per share and $0.03 per warrant. The filing also discloses substantial net losses, an accumulated deficit of $275.8 million as of December 31, 2025 and cash and cash equivalents of $20 thousand as of December 31, 2025, and notes substantial doubt about the company’s ability to continue as a going concern.